Open AccessPB1998: WEEKLY OPPOSED TO BI‐WEEKLY BORTEZOMIB AS PART OF INDUCTION CHEMOTHERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA IS BETTER TOLERATED AND EQUALLY EFFICIENT: REAL‐WORLD DATA FROM A RETROSPECTIVE AUDIT
Author(s) -
Faulkner L.,
Garg M.,
Suresh C.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000850824.39215.bd
Subject(s) - medicine , bortezomib , multiple myeloma , thalidomide , adverse effect , dosing , discontinuation , induction chemotherapy , chemotherapy , oncology , surgery